cat-lane
Cat lane / iStockphoto.com
12 October 2017

Sanofi invests $200m in flu vaccine production

Pharmaceutical company Sanofi has announced it is investing €170 million ($202 million) to expand an influenza vaccine production facility in France.

Sanofi said the new facility will expand its supply of VaxigripTetra to a maximum of 70 countries in six continents, and is the only facility of its kind in France.

“Influenza continues to be a major public health problem around the world, causing serious complications, hospitalisations and deaths,” said David Loew, executive vice president of Sanofi.

“This expansion reinforces Sanofi Pasteur’s ability to tackle this underestimated health challenge,” he added.

Sanofi plans to complete the expansion by 2021, subject to relevant health authority approvals, and will begin producing vaccines in this new facility in 2022.

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
16 August 2018   Pfizer has entered into a multi-year collaboration with immunotherapy company BioNTech to develop messenger ribonucleic acid-based vaccines for influenza.

More on this story

Americas
16 August 2018   Pfizer has entered into a multi-year collaboration with immunotherapy company BioNTech to develop messenger ribonucleic acid-based vaccines for influenza.

More on this story

Americas
16 August 2018   Pfizer has entered into a multi-year collaboration with immunotherapy company BioNTech to develop messenger ribonucleic acid-based vaccines for influenza.